1. MathersBM, DegenhardtL, PhillipsB, WiessingL, HickmanM, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733–1745.
2. World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS (2012) WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users: 2012 revision. Available: http://apps.who.int/iris/bitstream/10665/77969/1/9789241504379_eng.pdf. Accessed 1 January 2013.
3. MathersBM, DegenhardtL, AliH, WiessingL, HickmanM, et al. (2010) HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 375: 1014–1028.
4. StrathdeeSA, HallettTB, BobrovaN, RhodesT, BoothR, et al. (2010) HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376: 268–284.
5. DegenhardtL, MathersB, VickermanP, RhodesT, LatkinC, et al. (2010) Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376: 285–301.
6. GowingL, FarrellMF, BornemannR, SullivanLE, AliR (2011) Oral substitution treatment of injecting opioid uses for prevention of HIV infection. Cochrane Database Syst Rev 2011: CD004145.
7. MacArthurGJ, MinozziS, MartinN, VickermanP, DerenS, et al. (2012) Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 345: e5945.
8. BeyrerCB, Malinowska-SempruchK, KamarulzamanAK, KazatchkineM, SidibeM, et al. (2010) Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 376: 551–563.
9. WiessingL, LikataviciusG, KlempovaD, HedrichD, NardoneA, et al. (2009) Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. Am J Public Health 99: 1049–1052.
10. Van Den BergC, SmitC, Van BrusselG, CoutinhoR, PrinsM (2007) Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam cohort studies among drug users. Addiction 102: 1454–1462.
11. AlistarSS, OwensDK, BrandeauML (2011) Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med 8: e1000423 doi:10.1371/journal.pmed.1000423
12. AceijasC, StimsonGV, HickmanM, RhodesT (2004) Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18: 2295–2303.
13. ChenYMA, KuoSHS (2007) HIV-1 in Taiwan. Lancet 369: 623–625.
14. HuangYF, KuoHS, Lew-TingCY, TianF, YangCH, et al. (2011) Mortality among a cohort of drug users after their release from prison: an evaluation of the effectiveness of a harm reduction program in Taiwan. Addiction 106: 1437–1445.
15. FangCT, HsuHM, TwuSJ, ChenMY, ChangYY, et al. (2004) Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 190: 879–885.
16. LyuSY, SuLW, ChenYM (2011) Effects of education on harm-reduction programmes. Lancet 379: e28–e30.
17. HallHT, SongR, RhodesP, PrejeanJ, AnQ, et al. (2008) Estimation of HIV incidence in the United States. JAMA 300: 520–529.
18. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance (2011) When and how to use assays for recent infection to estimate HIV incidence at a population level. Geneva: World Health Organization. Available: http://www.who.int/diagnostics_laboratory/hiv_incidence_may13_final.pdf. Accessed 1 July 2013.
19. Taiwan Ministry of Justice (2012) [Statistics of justice in 2010.] Available: http://www.moj.gov.tw/public/Attachment/13118133562.pdf. Accessed 30 September 2012.
20. Taiwan Centers for Disease Control Department of Health Executive Yuan (2012) [HIV/AIDS statistics.] Available: http://www.cdc.gov.tw/professional/info.aspx?treeid=BEAC9C103DF952C4&nowtreeid=2F13020F8A921CCB&tid=5250BA9AD485D6C3. Accessed 1 December 2012.
21. DobbsT, KennedyS, PauCP, McDougalJS, ParekhBS (2004) Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 42: 2623–2628.
22. McWalterTA, WelteA (2010) Relating recent infection prevalence to incidence with a sub-population of non-progressors. J Math Biol 60: 687–710.
23. ParekhBS, HansonDL, HargroveJ, BransonB, GreenT, DobbsT, et al. (2012) Determination of mean recency period for estimation of HIV type 1 incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses 27: 265–273.
24. SuissaS (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167: 492–499.
25. AgrestiA, CoullBA (1998) Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 52: 119–126.
26. WoodE, KerrT, MarshallBD, LiK, ZhangR, et al. (2009) Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ Wood E 338: b1649.
27. BarrioG, BravoMJ, BrugalMT, DiezM, RegidorE, et al. (2012) Harm reduction interventions for drug injectors or heroin users in Spain: expanding coverage as the storm abates. Addiction 107: 1111–1122.
28. WilliamsAB, McNellyEA, WilliamsAE, D'AquilaRT (1992) Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care 4: 35–41.
29. MetzgerDS, WoodyGE, McLellanAT, O'BrienCP, DruleyP, et al. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6: 1049–1056.
30. SerpelloniG, CarrieriMP, RezzaG, MorgantiS, GommaM, et al. (1994) Methadone treatment as a determinant of HIV risk reduction among injection drug users: a nested case-control study. AIDS Care 6: 215–220.
31. MossAR, VranizanK, GorterR, BacchettiP, WattersJ, et al. (1994) HIV seroconversion in intravenous drug users in San Francisco, 1985–1990. AIDS 8: 223–231.
32. WodakA, CooneyA (2006) Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 41: 777–813.
33. Tilson H, Aramrattana A, Bozzette S (2007) Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence. Washington (District of Columbia): Institute of Medicine.
34. PalmateerN, KimberJ, HickmanM, HutchinsonS, RhodesT, et al. (2010) Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 105: 844–859.
35. TurnerKM, HutchinsonS, VickermanP, HopeV, CraineN, et al. (2011) The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106: 1978–1988.
36. MacArthurGJ, van VelzenE, PalmateerN, KimberJ, PharrisA, et al. (2014) Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy 25: 34–52.
37. JürgensR, BallA, VersterA (2009) Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 9: 57–66.
38. TaylorA, MunroA, AllenE, DunleavyK, CameronS, et al. (2013) Low incidence of HCV amongst prisoners in Scotland. Addiction 108: 1296–1304.
39. IguchiMY, LondonJA, ForgeNG, HickmanL, FainT, et al. (2002) Elements of well-being affected by criminalizing the drug user. Public Health Rep 117: S146–S150.